NASDAQ:FPRX Five Prime Therapeutics (FPRX) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free FPRX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$38.00▼$38.0050-Day Range$37.65▼$38.0052-Week Range$2.61▼$38.90VolumeN/AAverage Volume1.98 million shsMarket Capitalization$1.77 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Five Prime Therapeutics alerts: Email Address Ad Insider FinancialThousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage" About Five Prime Therapeutics Stock (NASDAQ:FPRX)Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.Read More Ad Insider FinancialThousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage" FPRX Stock News HeadlinesMarch 28, 2024 | seekingalpha.comCMMB Chemomab Therapeutics Ltd.October 15, 2023 | nbcnews.com33+ best October Prime Day deals you can still shop right nowApril 25, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… October 11, 2023 | benzinga.comNK Cell Therapy Pipeline, Clinical Trials Studies, Emerging Drugs, and FDA Approvals 2023 (Updated)October 3, 2023 | nypost.comThe Giants’ prime time TV demons are haunting them nowAugust 3, 2023 | forbes.comWhat Is The Prime Rate Today?July 23, 2023 | usatoday.comWant $5? Amazon Prime members can get $5 off a $50 Amazon eGift Card right nowJuly 5, 2023 | forbes.comPrime Therapeutics Hires New CEO To Lead Pharmacy Benefit Combination With MagellanRxApril 25, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… July 2, 2023 | usatoday.comGet ready for Amazon Prime Day 2023 with Prime membership discounts available nowMarch 30, 2023 | benzinga.comPrime Therapeutics announces Mostafa Kamal as presidentMarch 19, 2023 | finance.yahoo.comPrime Therapeutics and Magellan Rx to present seven managed care pharmacy research studies at AMCP conferenceMarch 1, 2023 | marketwatch.com2023-2029 Cystic Fibrosis (CF) Therapeutics Market Size and Porters Five Forces Analysis | Survey Report by Absolute ReportsOctober 27, 2022 | marketwatch.comMicrobiome Therapeutics Market 2022 Expected to Reach Significant Rate by 2025September 22, 2021 | feeds.bizjournals.comOral Covid vaccine developer nails down Peninsula spaceAugust 3, 2021 | nasdaq.comFive Prime Therapeutics, Inc. Common Stock (FPRX)See More Headlines Receive FPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Five Prime Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2020Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:FPRX CUSIPN/A CIK1175505 Webwww.fiveprime.com Phone415-365-5600FaxN/AEmployees87Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-137,200,000.00 Net Margins-554.71% Pretax MarginN/A Return on Equity-75.84% Return on Assets-49.08% Debt Debt-to-Equity RatioN/A Current Ratio5.35 Quick Ratio5.35 Sales & Book Value Annual Sales$14.87 million Price / Sales119.01 Cash FlowN/A Price / Cash FlowN/A Book Value$4.13 per share Price / Book9.20Miscellaneous Outstanding Shares46,572,000Free FloatN/AMarket Cap$1.77 billion OptionableOptionable Beta4.40 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Helen Louise Collins (Age 58)Exec. VP & Chief Medical Officer Comp: $637.25kMr. Francis W. Sarena (Age 50)Chief Strategy Officer & Sec. Comp: $646.49kMr. Thomas Civik (Age 52)Pres, CEO & Director Mr. David V. Smith M.B.A. (Age 61)Exec. VP & CFO Mr. David White (Age 57)Principal Accounting Officer Mr. Martin ForrestVP of Investor Relations & Corp. CommunicationsDr. Nallakkan S. ArvindanSr. VP of Strategic Technology OperationsMore ExecutivesKey CompetitorsSyndax PharmaceuticalsNASDAQ:SNDXAgios PharmaceuticalsNASDAQ:AGIOSchrödingerNASDAQ:SDGRCatalyst PharmaceuticalsNASDAQ:CPRXStructure TherapeuticsNASDAQ:GPCRView All Competitors FPRX Stock Analysis - Frequently Asked Questions How were Five Prime Therapeutics' earnings last quarter? Five Prime Therapeutics, Inc. (NASDAQ:FPRX) issued its quarterly earnings data on Friday, November, 6th. The biotechnology company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by $0.14. The biotechnology company had revenue of $2.05 million for the quarter, compared to the consensus estimate of $3.50 million. Five Prime Therapeutics had a negative trailing twelve-month return on equity of 75.84% and a negative net margin of 554.71%. Read the conference call transcript. What other stocks do shareholders of Five Prime Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Five Prime Therapeutics investors own include Pfizer (PFE), Nektar Therapeutics (NKTR), OPKO Health (OPK), TG Therapeutics (TGTX), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), ImmunoGen (IMGN), VBI Vaccines (VBIV) and Mallinckrodt (MNK). This page (NASDAQ:FPRX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThese AI trades triggered this morning (545% return)Prosper Trading AcademyRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldYour Money is Not SafeAmerican Alternativetop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe World's First "$20 Trillion Drug?"Behind the MarketsThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Five Prime Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.